Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).
暂无分享,去创建一个
S. Haffner | G. Howard | L. Mykkänen | R. D'Agostino | R. Tracy | A. Festa | R. Tracy | S. Haffner | L. Mykkänen
[1] Joël Ménard,et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.
[2] J. Wright,et al. Expression of C-reactive protein by alveolar macrophages. , 1996, Journal of immunology.
[3] S. Haffner,et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[4] R. Bergman,et al. The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results. , 1995, Annals of epidemiology.
[5] D. Owens,et al. Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins. , 1989, The Biochemical journal.
[6] S. Coppack,et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[7] P. Ridker,et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.
[8] W. Koenig,et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[9] R. Tracy,et al. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. , 1997, Clinical chemistry.
[10] R. Tracy,et al. The measurement of fibrinogen in population-based research. Studies on instrumentation and methodology. , 1994, Archives of pathology & laboratory medicine.
[11] R. Grimble. Nutrition and Cytokine Action , 1990, Nutrition Research Reviews.
[12] H. Baumann,et al. Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes. , 1992, Molecular and cellular biology.
[13] D. Strachan,et al. C Reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study , 1996, BMJ.
[14] M. Pepys,et al. C-reactive protein: binding to lipids and lipoproteins. , 1985, International review of experimental pathology.
[15] C. Yutani,et al. Immunohistochemical localization of C‐reactive protein‐binding sites in human atherosclerotic aortic lesions by a modified streptavidin‐biotin‐staining method , 1995, Pathology international.
[16] S. Thompson,et al. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.
[17] R. Bergman,et al. Increased Insulin Resistance and Insulin Secretion in Nondiabetic African-Americans and Hispanics Compared With Non-Hispanic Whites: The Insulin Resistance Atherosclerosis Study , 1996, Diabetes.
[18] M. A. Crook,et al. Is Type II diabetes mellitus a disease of the innate immune system? , 1998, Diabetologia.
[19] U. Smith,et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. , 1990, Metabolism: clinical and experimental.
[20] Richard N Bergman,et al. Reduced Sample Number for Calculation of Insulin Sensitivity and Glucose Effectiveness From the Minimal Model: Suitability for Use in Population Studies , 1993, Diabetes.
[21] L H Kuller,et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[22] I. T. Ten Berge,et al. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. , 1996, Journal of immunology.
[23] M. Laakso,et al. Asymptomatic atherosclerosis and insulin resistance. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.
[24] R N Bergman,et al. Assessment of insulin sensitivity in vivo. , 1985, Endocrine reviews.
[25] V. Herbert,et al. Coated charcoal immunoassay of insulin. , 1965, The Journal of clinical endocrinology and metabolism.
[26] J. Stengård,et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.
[27] L. Kuller,et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[28] R N Bergman,et al. Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. , 1990, The Journal of clinical endocrinology and metabolism.
[29] A. Döring,et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. , 1999, Circulation.
[30] I. Kushner. Regulation of the Acute Phase Response by Cytokines , 2015, Perspectives in biology and medicine.
[31] P. Weber,et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. , 1989, The New England journal of medicine.
[32] R N Bergman,et al. MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. , 1986, Computer methods and programs in biomedicine.
[33] A. Döring,et al. C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men , 1998 .
[34] M. Pepys,et al. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. , 1993, The Journal of clinical investigation.
[35] Harry,et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. , 1993, Blood.
[36] R. Tracy. Inflammation in cardiovascular disease: cart, horse, or both? , 1998, Circulation.
[37] S. Thompson,et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.
[38] G. Cruciani,et al. Physiological Increments in Plasma Insulin Concentrations Have Selective and Different Effects on Synthesis of Hepatic Proteins in Normal Humans , 1993, Diabetes.
[39] G. Dagenais,et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. , 1996, The New England journal of medicine.